ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Half Year Results
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, August 5, 2008. In the second quarter of 2008, Eckert & Ziegler
Strahlen- und Medizintechnik AG (ISIN DE0005659700), a globally active
company specializing in isotope technology applications in industry and
medicine, increased its sales to EUR 18.6 million, thus achieving a rise of
24% on the half-yearly sales in the reference period last year, to EUR 32.8
million. The Pankow concern thus considerably exceeded a half-yearly sales
figure of EUR 30 million for the first time ever.
The company’s profit after taxes and other shareholders’ holdings was EUR
9.4 million for the half-year, or EUR 2.98 per share. Of this figure,
around EUR 7.6 million or EUR 2.41 per share originate from one-off
extraordinary gains from the first-time consolidation of Belgian company
International Brachytherapy (IBt). Eckert & Ziegler also achieved very good
results in the half-year if the extraordinary gains are disregarded. Its
operating result rose by 47% compared with the reference period in the
previous year, to EUR 4.2 million or EUR 1.35 per share; the result without
minority interests and adjusted for special items grew by 23% to EUR 1.8
million or EUR 0.57 per share.
The segment with the highest turnover in these six months was the Nuclear
Imaging and Industry segment, whose sales increased by 12% on those in the
same period last year, to EUR 14.4 million. On a US dollar basis, the
segment’s sales grew even more, by 26%. The increase can be attributed to
the business generated with the new generation of robust drill hole sources
and the catching up on delivery delays which was announced in the last
quarterly report.
In the Radiopharmaceuticals segment, sales more than doubled from EUR 3.1
million to EUR 6.8 million. The lion’s share of this growth was recorded by
the Modular Lab product group, with an increase of EUR 1.4 million.
The Therapy segment’s sales rose to EUR 11.6 million, and within the
segment sales of implants used to treat prostate cancer were up by 68%.
The Executive Board
Your contact in the event of queries:
Thomas Scheuch
Investor Relations
Eckert & Ziegler AG
Robert-Rössle-Str. 10
D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-139
Fax: +49 (0) 30 / 94 10 84-112
E-mail: thomas.scheuch@ezag.de
www.ezag.de
05.08.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: thomas.scheuch@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------
